Platelet aggregation and plasma levels of acetylsalicylic acid in stroke patients on long-term treatment with an enteric-coated aspirin formulation

1984 ◽  
Vol 27 (3) ◽  
pp. 363-365 ◽  
Author(s):  
M. Britton ◽  
A. Melander ◽  
J. Svensson ◽  
E. W�hlin-Boll
Keyword(s):  
Platelet Aggregation ◽  
Acetylsalicylic Acid ◽  
Plasma Levels ◽  
Term Treatment ◽  
Stroke Patients ◽  
Long Term Treatment ◽  
Enteric Coated Aspirin ◽  
Enteric Coated

P.2.044 Clozapine, norclozapine plasma levels during a long term treatment of schizophrenic patients

1997 ◽  
Vol 7 ◽  
pp. S207
Author(s):  
M.C. Mauri ◽  
S. Bravin ◽  
Ricci ◽  
L. Boscati ◽  
E. Giuliani ◽  
...  
Keyword(s):  
Plasma Levels ◽  
Term Treatment ◽  
Long Term Treatment ◽  
Schizophrenic Patients

scholarly journals Post-stroke Rehabilitation of Severe Upper Limb Paresis in Germany – Toward Long-Term Treatment With Brain-Computer Interfaces

2021 ◽  
Vol 12 ◽  
Author(s):  
Cornelius Angerhöfer ◽  
Annalisa Colucci ◽  
Mareike Vermehren ◽  
Volker Hömberg ◽  
Surjo R. Soekadar
Keyword(s):  
Upper Limb ◽  
Hand Function ◽  
Treatment Strategies ◽  
Term Treatment ◽  
Brain Computer Interfaces ◽  
Stroke Patients ◽  
Computer Interfaces ◽  
Long Term Treatment ◽  
Upper Limb Paresis

Severe upper limb paresis can represent an immense burden for stroke survivors. Given the rising prevalence of stroke, restoration of severe upper limb motor impairment remains a major challenge for rehabilitation medicine because effective treatment strategies are lacking. Commonly applied interventions in Germany, such as mirror therapy and impairment-oriented training, are limited in efficacy, demanding for new strategies to be found. By translating brain signals into control commands of external devices, brain-computer interfaces (BCIs) and brain-machine interfaces (BMIs) represent promising, neurotechnology-based alternatives for stroke patients with highly restricted arm and hand function. In this mini-review, we outline perspectives on how BCI-based therapy can be integrated into the different stages of neurorehabilitation in Germany to meet a long-term treatment approach: We found that it is most appropriate to start therapy with BCI-based neurofeedback immediately after early rehabilitation. BCI-driven functional electrical stimulation (FES) and BMI robotic therapy are well suited for subsequent post hospital curative treatment in the subacute stage. BCI-based hand exoskeleton training can be continued within outpatient occupational therapy to further improve hand function and address motivational issues in chronic stroke patients. Once the rehabilitation potential is exhausted, BCI technology can be used to drive assistive devices to compensate for impaired function. However, there are several challenges yet to overcome before such long-term treatment strategies can be implemented within broad clinical application: 1. developing reliable BCI systems with better usability; 2. conducting more research to improve BCI training paradigms and 3. establishing reliable methods to identify suitable patients.

Antiaggregatory Effects of Picotamide in Long-Term Treatment: A 2-Year, Double-Blind Placebo-Controlled Trial

1997 ◽  
Vol 2 (4) ◽  
pp. 292-295 ◽  
Author(s):  
Manlio Cocozza ◽  
Massimo Milani ◽  
Tommaso Picano ◽  
Ugo Oliviero ◽  
Nicola Russo ◽  
...  
Keyword(s):  
Platelet Aggregation ◽  
Ex Vivo ◽  
Controlled Trial ◽  
Term Treatment ◽  
Significant Inhibition ◽  
Diabetic Patients ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Long Term Treatment

The ex vivo antiaggregatory activity of picotamide, a dual antithromboxane agent, was assessed to find whether it was maintained in long-term treatment. In a double-blind, placebo-controlled 2-year study, 50 type 2 diabetic patients (35 men and 15 women; mean age 66 ± 5 years) were enrolled and randomly given picotamide, 300 mg t.i.d. or the corresponding placebo. Platelet aggregation studies were performed at baseline and after 1, 3, 6, 12, 18 and 24 months. Compliance to the treatment was assessed by pill count at each visit. Forty-nine patients concluded the study. Starting from month 1, compared with placebo, picotamide-treated patients showed a significant inhibition of agonist-induced (ADP, arachidonic acid and collagen) platelet aggregation (–41%). The antiaggregatory effect was maintained throughout the study. At month 24, in the picotamide group, platelet aggregation was significantly lower compared with placebo (–30%). After 24 months of treatment, 20 out of 23 (86%) picotamide-treated patients showed a significant inhibition of platelet aggregation, whereas the remaining three patients had a normal platelet response. During the study, 12 patients suffered from thrombotic events of death: nine in the placebo group and three in the picotamide group, respectively. It was concluded that picotamide maintains its antiaggregatory effect, in long-term treatment, in more than 85% of patients.

Propafenone for refractory ventricular arrhythmias: Correlation with drug plasma levels during long-term treatment

1984 ◽  
Vol 54 (8) ◽  
pp. 1008-1014 ◽  
Author(s):  
Franco Naccarella ◽  
Daniele Bracchetti ◽  
Massimo Palmieri ◽  
Bruno Marchesini ◽  
Ettore Ambrosioni
Keyword(s):  
Plasma Levels ◽  
Ventricular Arrhythmias ◽  
Term Treatment ◽  
Drug Plasma ◽  
Long Term Treatment ◽  
Drug Plasma Levels

Alteration of pharmacokinetics of lepirudin caused by anti-lepirudin antibodies occurring after long-term subcutaneous treatment in a patient with recurrent VTE due to Behcet’s disease

VASA ◽  
2010 ◽  
Vol 39 (1) ◽  
pp. 103-107 ◽  
Author(s):  
Linnemann ◽  
Greinacher ◽  
Lindhoff-Last
Keyword(s):  
Anticoagulant Therapy ◽  
Plasma Levels ◽  
High Titer ◽  
Vitamin K Antagonists ◽  
Term Treatment ◽  
Bleeding Complications ◽  
Thrombin Inhibitor ◽  
Long Term Treatment ◽  
Recurrent Vte

The direct thrombin inhibitor lepirudin is mainly applied in heparin-induced thrombocytopenia. We report here the case of a 37-year-old kurdish woman in whom Behcet’s disease was diagnosed in 1998 when she presented with a Budd Chiari syndrome (BCS) complicated by pulmonary embolism. Recurrent venous thromboembolism (VTE) occurred despite anticoagulant therapy with UFH, LMWH or phenprocoumon and various immunosuppressive therapy regimens. In 2001, when BCS recurred ultimately i.v. lepirudin was administered. When the patient improved and remained clinically stable lepirudin was applied subcutaneously. During long-term treatment with twice-daily 50 mg no further VTE was observed over the following years. Additionally, no bleeding complications occurred. In May 2005 anticoagulant therapy was switched to phenprocoumon. BCS reoccurred when INR values were suboptimal in February 2007, and lepirudin treatment was immediately restarted. After admission the patient received 50 mg b.i.d. lepirudin s.c. with plasma levels in the therapeutic range (0.5-1.0 mg / l). Over the following months, lepirudin levels repeatedly exceeded the upper limit of this range and the dosage was stepwise reduced. Finally, 20 mg b.i.d. were sufficient to obtain therapeutic levels. Renal function was normal, but lepirudin antibodies were present in high titer, as assessed by ELISA. We suppose that these antibodies reduce renal filtration of lepirudin thus leading to increased plasma levels. This case is an example for successful long-term therapeutic-dose anticoagulation with s.c. lepirudin in a patient with Behcet’s disease and recurrent VTE despite therapeutic anticoagulant therapy with LMWH or vitamin K antagonists. However, frequent measurement of lepirudin plasma levels is needed. If stepwise dose lowering is required over time, the presence of lepirudin antibodies should be considered.

Sign in / Sign up

Export Citation Format

Share Document